TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The CDC’s updated 2026 antimicrobial-resistance report identifies 19 pathogens as threats and six more as potential emerging threats. Together, the listed pathogens are estimated to cause 9.7 million infections and 50,800 deaths in the United States each year; the report also moves C. difficile from the urgent to the serious category.
The CDC’s updated 2026 antimicrobial-resistance report names 19 pathogens as public health threats and estimates they cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens are in the agency’s top-tier “urgent” category, while six additional pathogens are on a watch list.
The four pathogens designated urgent threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The CDC’s categories range from “concerning” and “serious” to “urgent,” reflecting the agency’s assessment of the threats and the need for action. The report’s overall annual estimates cover all 19 listed pathogens, not just the four in the urgent category.
The report also tracks changes in the threat picture. Clostridioides difficile moved from urgent to serious; the source report says this shift was driven in part by infection-prevention measures that have reduced cases since 2011. Drug-resistant N. meningitidis was added as a serious threat. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria are among the additions to the watch list, which identifies potential threats whose disease burden is uncertain.
Figures for specific pathogens illustrate different aspects of the problem. U.S. reports of C. auris cases rose from 48 in 2016 to 4,523 in 2023. In 2023, carbapenem-resistant Acinetobacter was associated with 9,497 U.S. hospitalizations and an estimated 817 deaths; carbapenem-resistant Enterobacterales was associated with 14,878 hospitalizations and an estimated 1,252 deaths. The CDC’s report, as summarized by MedPage Today, also estimates 787,000 U.S. infections from drug-resistant gonorrhea in 2023.
How Resistance Affects Patient Care
Antimicrobial resistance can make infections harder to treat when medicines that once worked become less effective. The risks are especially serious in hospitals and other care settings, where patients may already be ill, use devices such as catheters or ventilators, or need procedures that depend on infection prevention and effective antibiotics.
Wendy Armstrong, president of the Infectious Diseases Society of America, said resistant infections can prolong hospital stays and increase health care costs. She also warned that they can make it more difficult for clinicians to provide care such as chemotherapy, organ transplants and joint replacements safely. These are her comments on the report’s implications, not a separate estimate of how many procedures are affected.
The report’s national totals offer a measure of the scale, but the pathogen-specific numbers show why the issue is not confined to one type of infection. Drug-resistant organisms can affect people in hospitals, nursing homes and the wider community. For readers, the figures point to a public health challenge that can affect both treatment choices and the safety of routine or complex medical care.
Popular right now
TCL T7 Series 85-Inch 4K 144Hz QLED Smart Google TV
Apple AirPods Pro 3 Wireless Earbuds with Active Noise Cancellation
Ninja DualZone Air Fryer 10 Qt Smart 6-in-1 Grey (DZ950)
As an affiliate, we earn on qualifying purchases.
What Changed in the 2026 List
The CDC’s updated report assesses antimicrobial-resistant pathogens and assigns them threat categories. The current summary identifies 19 pathogens in the threat assessment and six on a watch list. A watch-list designation signals that an organism could become a potential threat, while its disease burden or future impact remains uncertain; it is not the same as being placed in the urgent category.
Several listed organisms have distinct risk profiles. Carbapenem-resistant Acinetobacter is a concern in hospitals and nursing homes and can spread through contaminated surfaces or equipment. Carbapenem-resistant Enterobacterales include resistant strains of E. coli and Klebsiella; the source report identifies patients using ventilators or catheters, and those receiving prolonged antibiotic courses, as being at greater risk. Drug-resistant gonorrhea can limit treatment options for a common sexually transmitted infection.
Some developments cut across the threat list. The report says infection-prevention efforts have helped lower C. difficile cases since 2011, contributing to its lower category. For gonorrhea, two antibiotics—gepotidacin, marketed as Blujepa, and zoliflodacin, marketed as Nuzolvence—received FDA approval in the previous year, according to the source report. It describes them as the first new antibiotics for gonorrhea in decades.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Threat Estimates
The 50,800 annual deaths and 9.7 million infections are estimates for the pathogens collectively. The supplied summary does not provide the underlying calculation method, a specific period used to derive those totals, or a breakdown of the overall figures by pathogen. Individual figures cited for Acinetobacter, Enterobacterales and gonorrhea refer to 2023 and should not be read as current-year counts.
The watch-list pathogens are described as potential threats, and the CDC’s summary says their disease burden is uncertain. The information provided does not say how many infections or deaths those organisms currently cause in the United States. It also does not detail how the agency will measure changes in their threat levels or when the next assessment will be released.
For the C. difficile category change, the source identifies prevention measures as one factor in the decline since 2011, but does not quantify how much of the change those measures account for. The supplied material likewise does not give further detail on the individual category methodology or the contribution of other factors to the pathogen trends.
Policy and Surveillance Ahead
The CDC’s report sets out the agency’s current assessment; the next steps for public health and health care systems include continued monitoring, infection prevention and attention to treatment options. The supplied material does not announce a specific CDC action plan or timetable tied to the report, so the agency’s next operational milestones are not clear from the information available.
Policy action is also uncertain. Armstrong urged Congress to pass the PASTEUR Act, which she said would create a federal program to support development of antimicrobial drugs for the most threatening infections. According to the source report, versions of the legislation remained stalled in congressional committees. No passage date or further legislative schedule was provided.
Further updates will be needed to show whether the new watch-list organisms rise to higher threat categories, whether prevention efforts continue to affect C. difficile rates, and how the burden of drug-resistant infections changes over time. The report’s 2023 pathogen-specific figures provide a reference point, but they do not establish what those counts are in 2026.
Key Questions
What does the CDC estimate about infections and deaths?
The CDC estimates that the pathogens covered in its 2026 report cause 9.7 million infections and 50,800 deaths each year in the United States. Those are combined estimates; the supplied summary does not provide a pathogen-by-pathogen breakdown of the totals.
Which pathogens are classified as urgent threats?
The four urgent drug-resistant pathogens named in the report summary are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The report moved Clostridioides difficile from urgent to serious. The source says successful infection-prevention measures contributed to falling case numbers since 2011, but it does not quantify the effect of those measures or identify all factors behind the change.
What is the CDC’s watch list?
The watch list includes pathogens considered potential emerging threats whose disease burden is uncertain. The 2026 summary names six watch-list pathogens, including drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria.
What is the status of the PASTEUR Act?
Wendy Armstrong called for the bill’s passage, describing it as a proposed federal program to support antimicrobial drug development for the most threatening infections. The source report says versions of the bill remained stalled in congressional committees; it does not provide a later legislative update.
Source: medpagetoday.com
